Last updated on March 2016

A Phase 2b, Randomized, Doubl-blind, Placebo-controlled, Parallel-group, Dose-ranging-finding Trial of XXXXX Administered Orally for 8 Weeks to Patients with Symptomatic Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Gastroesophageal Reflux Disease (GERD) | Gastrointestinal Diseases and Disorders
  • Age: 18 Years
  • Gender: Male or Female

Eligibility Criteria:

  • Male or nonpregnant females 18 years old and older
  • Has a diagnosis of GERD and reports experiencing GERD symptoms (heartburn or regurgitation) on ≥ 4 days per week during the 8 weeks before the Screening Visit while taking standard once daily PPI therapy.
  • Has been receiving standard labeled dose once daily, proton pump inhibitors therapy for a minimum of 8 weeks before the Screening Visit.
  • An EGD followed by approximately 48 to 96 hours of pH monitoring (with a Bravo® device) during the Screening Period (while the patient continues taking their PPIs) demonstrates 1 or more of the following:
    • Erosive esophagitis on EGD
    • Evidence of pathological acid reflux
  • Reports heartburn severity
  • Compliant with daily eDiary completion

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.